INmune Bio's XPro1595 shows promising results in Phase 2 MINDFuL trial for Alzheimer's.

INmune Bio announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease patients with elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer's Disease conference in San Diego. The new analyses further validate the Company's strategy of targeting inflammation-driven AD, a large underserved subset with significant commercial potential.